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Abstract
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the effectiveness of tobacco cessation therapy offered concurrently with treatment for
drug and alcohol addiction.
BACKGROUND
Tobacco kills up to half its users, accounting for nearly six million deaths annually
worldwide (WHO 2012). Tobacco-related disease is the leading preventable cause of death
in the United States (Mokdad 2004), and smoking rates in alcohol, drug abuse, and mental
health (ADM) populations are two to four times that of the general population (Kalman
2005). Recent estimates suggest these groups suffer approximately half of all smoking-
related deaths (Mauer 2006; Schroeder 2009; Williams 2006). Less than one quarter of the
U.S. population (23%) smokes and overall smoking rates have declined since the 1960s
(Schroeder 2004). In ADM populations, however, smoking rates have remained constant
(Lamberg 2004).
The health risks of smoking in ADM populations have frequently been viewed as less
relevant than the perceived therapeutic benefits of smoking, which were presumed to calm
patients with psychiatric disorders and reduce the risk of relapse for recovering addicts.
These beliefs in the benefits of smoking in this population persist despite empirical findings
showing the opposite effects (Guydish 2007; Philip Morris 1994; Psychiatric News 1994).
They also discourage the enactment of policy interventions that would reduce the
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disproportionate deaths from tobacco use that ADM populations experience (Apollonio
2005; Gudrais 2008).
This review specifically addresses tobacco cessation interventions in alcohol and drug abuse
populations (other reviews address mental health populations, see Tsoi 2010 and van der
Meer 2009). In the United States, studies estimate that nearly 13% of the population is
addicted to alcohol, other drugs, or both (CASA 2012; NIDA 2012). The median smoking
rate among adults in substance abuse treatment is 76%(Guydish 2011).Due to high smoking
rates, individuals in these populations face a disproportionate risk of death due to tobacco
use. Alcohol addicts, for example, have a 51% risk of dying from tobacco-related disease,
compared to a 34% risk of dying from alcohol-related causes (Hurt 1996). Surveys also
suggest that drug and alcohol addicts in treatment or recovery want to quit smoking and are
interested in receiving smoking cessation therapy (Joseph 2003). As a result, researchers
now argue that access to smoking cessation therapy during treatment would be clinically
appropriate and would dramatically reduce smoking-related deaths in these populations
(Abrams 2010; Baca 2009; Levy 2010).
Despite these findings, neglect of tobacco addiction in ADM populations remains common.
This neglect is sometimes attributed to the stigma and marginalisation faced by those
experiencing mental illness or in treatment for substance abuse (Schroeder 2008). In
addition, questions remain as to how to treat tobacco comorbidity and whether tobacco
cessation therapy should be offered during substance abuse treatment or delayed. Concurrent
treatment of tobacco addiction has been limited due to staff fears that recovery from other
addictions would be compromised if clients tried to simultaneously quit smoking (Goldsmith
1993; Richter 2006). When surveyed, only one-third of US respondents representing alcohol
treatment programs agreed that clients in treatment should be encouraged to quit smoking
(Bobo 1995), and similar results have been reported for providers in Australia and
Switzerland (Walsh 2005; Zullino 2000).
Description of the condition
Tobacco use in populations dealing with substance abuse causes significant morbidity and
mortality. It is not clear how or when to address tobacco addiction in these populations.
Substance abuse is highly correlated with mental illness (dual diagnosis) and 60% of people
with a substance use disorder also suffer from mental illness (NIDA 2007). Smokers with a
history of alcoholism are more nicotine dependent than those without a history of alcoholism
(Hurt 2003;Ward 2012), and these individuals are also less likely to quit smoking (Hays
1999). Former alcoholics that seek to quit smoking request more pharmacotherapy than
smokers without a history of alcoholism (Hughes 2000).
Description of the intervention
Integrating smoking cessation treatment into chemical dependency units remains
challenging. First, many of the individuals staffing substance abuse treatment centres are
smokers themselves. Staff acceptance is a key factor and changing staff attitudes is a first
major step toward eventually changing staff behavior (Hurt 1995). Second, individuals in
substance abuse treatment do not receive care from a single source; they may begin with
residential care and move to outpatient care over time or complete all treatment as
outpatients. As either inpatients or outpatients, individuals seeking treatment for addiction
may be counselled on tobacco cessation either by staff dealing with other addictions or by
staff dealing specifically with tobacco-related disease. Pharmacotherapy is typically
prescribed by a physician that handles medical issues for the client, but not issues relating to
addictions. Finally, the best form of treatment has not been established. Tobacco cessation
treatment can be in the form of counselling, pharmacotherapy, or both.
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Given the existing literature, it is not possible to assess the treatment effects of receiving
addiction treatment from current smokers, or the effect of having multiple care providers.
However, in this review, we assess the effects of different types of interventions:
counselling, nicotine replacement therapy (NRT), non-NRT pharmacotherapy, or a
combination thereof.
How the intervention might work
Tobacco cessation treatments provide: motivation and support for change through
counselling, treatment for withdrawal symptoms using NRT or non-NRT pharmacotherapy,
or a combination of these. NRT success rates in the general population, when combined with
counselling, range from 11% to 30% (Campbell 2003). As a result, combination therapy is
recommended in the general population (Ebbert 2007). For individuals with more severe
tobacco dependence, a group that encompasses most substance abusers, some research
suggests both combination therapy and the use of multiple pharmacological agents (Hurt
2009).
Why it is important to do this review
Most studies demonstrate that adding smoking cessation therapy to substance abuse
treatment programs yields higher overall drug and alcohol abstinence (Tsoh 2011). We will
systematically review these studies and provide a meta-analysis of their results. The results
will identify whether or not tobacco cessation therapy offered concurrently with drug or
alcohol treatment increases abstinence from tobacco, alcohol and other drugs. Our findings
will help assess whether tobacco cessation therapy should be offered concurrently with
treatment for other addictive drugs or delayed. Alcoholics and substance abusers have
unique needs and additional dependencies that may demand differential tobacco cessation
treatment. For example, recovering addicts may require more pharmacotherapy to treat
withdrawal symptoms because they are more nicotine dependent. This review will compare
the timing of tobacco cessation treatment and the types of treatment in order to identify the
best options for recovering addicts.
An earlier review was conducted in this area (Prochaska 2004). This analysis will update
those findings and expand on the previous review by considering four specific interventions:
counselling, NRT, pharmacotherapy, and combined interventions, as well as providing
subgroup analyses by stage of recovery, drug of choice, and type of treatment.
OBJECTIVES
To evaluate the effectiveness of tobacco cessation therapy offered concurrently with
treatment for drug and alcohol addiction.
METHODS
Criteria for considering studies for this review
Types of studies—Randomized controlled trials (RCTs) and cluster-RCTs, with no
exclusions based on language of publication or publication status.
Types of participants—Adults aged 18 years or older who are undergoing inpatient or
outpatient treatment for drug or alcohol addiction and are participating in a study to
encourage tobacco cessation during substance abuse treatment. Interventions may target
either groups (e.g. the population of a single clinic) or individuals (e.g. patients at a single
clinic). We will distinguish between studies that randomize participants within clinics and
those that randomize by clinic site (cluster randomization). We will include information on
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the nature of the addiction(s) for which the individual originally sought treatment.
Participants in the included studies need not have been selected based on level of smoking
(e.g. daily smokers) or their presumed suitability for particular interventions.
Types of interventions—We will include interventions designed to encourage tobacco
cessation. Interventions will be organized by type in the following categories:
1. Counseling only, both individual and group sessions, delivered in a clinic setting
for tobacco cessation purposes during the course of existing addictions treatment,
or in addition to existing interventions for other addictions;
2. Nicotine replacement therapy (NRT) of all modalities (e.g. gum, patch), both
prescription and over-the-counter, offered to individuals for tobacco cessation
purposes during the course of existing addictions treatment;
3. Non-NRT pharmacology (e.g. varenicline [Chantix, Champix] or bupropion
[Zyban]) offered to individuals for tobacco cessation purposes during the course of
existing addictions treatment;
4. A combination of any of the above methods.
The controls in these studies must be individuals in substance abuse treatment who were
offered different tobacco cessation therapies, delayed therapy, lower levels of treatment, or
no tobacco-related addiction treatment.
Types of outcome measures
Primary outcomes: The preferred primary outcome will be point prevalence tobacco
abstinence, as defined by self-reported tobacco use or through biochemical validation (e.g.
urinary cotinine) at the longest follow-up period reported in each study. These results will be
measured as the number of participants who are abstinent in each condition (treatment or
control) at final follow-up relative to the number of participants enrolled in the study. We
will use biochemically validated abstinence measures if they are supplied. We rely on point
prevalence abstinence rather than continuous abstinence, where both are reported, due to the
difficulty of follow-up within this population. No minimum length of follow-up will be
required for studies to be included.
We will record the definition of tobacco use as defined by each study. This can include
current daily use, current occasional use, or, in the case of individuals released to substance
abuse treatment after incarceration, regular tobacco use before arrest.
We will consider whether abstinence is sustainable by considering whether abstinence rates
increase or decrease at the longest follow-up point, relative to earlier post-intervention
follow-ups.
Studies reporting reduced smoking rather than abstinence will be reported separately from
studies that report abstinence. These results will be measured by the number of cigarettes
that participants in each condition (treatment or control) report smoking per day at the
longest follow-up period reported in each study. We will use biochemically validated
measures (e.g. urinary cotinine) to validate reduced smoking if they are available. If
outcomes are reported separately for different categories of baseline users we will extract
data for all outcomes. We will exclude studies that measure interventions included in the
criteria above, but that do not report the primary outcome measure.
Secondary outcomes: If reported, the following secondary outcomes will be extracted:
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1. Point prevalence abstinence from alcohol and other drugs as defined by self-
reported drug use or through biochemical validation at the longest follow-up period
reported in the study. We will assess abstinence from alcohol and other drugs using
the same methods proposed for assessing tobacco abstinence. Similarly, studies
reporting reduced drug use rather than abstinence will be reported separately from
studies reporting abstinence. If outcomes are reported separately for different
categories of baseline users we will extract data for all outcomes.
2. The costs of interventions will be assessed using the reporting of individual studies
included in the review if these data are available. We anticipate that cost data
would need to be assessed by narrative synthesis, as there are no standardized
reporting measures for costs, or methods of objective verification for reported
costs.
Search methods for identification of studies
Electronic searches—We will search the Cochrane Tobacco Addiction Group
Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), and
MEDLINE. The Specialised Register includes reports of trials identified from systematic
and sensitive searches of resources, including MEDLINE, EMBASE and PsycINFO, for
reports of trials of interventions for smoking cessation and prevention (see the Tobacco
Addiction Group Module in the Cochrane Library for full details). The Specialised Register
search will use topic related keywords and free text terms covering alcohol abuse and drug
dependence. The CENTRAL search will combine topic related terms and terms related to
smoking cessation. The MEDLINE search will combine substance abuse terms, smoking
cessation terms and study design terms (e.g., randomized controlled trial, controlled clinical
trial). See Appendix 1 for the full MEDLINE search strategy.
Searching other resources—We will search through the grey literature, including
conference abstracts from the Society for Research on Nicotine and Tobacco and the
ProQuest database of digital dissertations.
We will search all registered trials through the National Institutes of Health’s
www.clinicaltrials.gov site.
Data collection and analysis
Selection of studies—From the title, abstract, or descriptors, one reviewer (RP) will
independently review the literature searches to identify potentially relevant trials.
Data extraction and management—One reviewer (RP) will extract data for the trials
using a standardized data extraction form prior to entry into The Cochrane Collaboration
software program, Review Manager 5.1. Authors will be contacted to obtain missing or raw
data. All studies that clearly do not meet the inclusion criteria in terms of study design,
population or interventions will be excluded. RP will extract the data, which will be checked
by a second reviewer (DA). The risks of bias for each included study will be extracted by
two independent reviewers (DA and RP).
The following information will be extracted, using a tool developed by LB and modified by
DA:
1. methods, including the setting of the trial, study design, study objectives, study
site(s), definition of tobacco use, methods of participant recruitment, types of
treatment interventions, proposed outcome measures, and methods of analysis;
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2. participant data, including age, gender, ethnicity, socio-economic status, and n-
values for eligibility, recruitment and completion;
3. interventions, including descriptions of interventions, duration of treatment,
delivery of intervention, type and duration of behavioural support (if applicable)
and components of treatment in the control group;
4. outcomes, including methods of data collection for results, definitions of
abstinence, abstinence from tobacco, abstinence from other drugs, changes in
abstinence rates over time, cost of treatment (when available), validation, follow-up
period, other follow-ups in the course of the study, and other data as defined under’
Types of outcome measures’ in this protocol, and;
5. risks of bias, including methods of sequence generation for randomization,
allocation concealment, blinding, incomplete outcome data, selective outcome
reporting, contamination, clustering by clinic site, imbalance of outcome measures
at baseline, comparability of intervention and control group characteristics at
baseline, protection against contamination, selective recruitment of participants and
other potential threats to validity.
Assessment of risk of bias in included studies—Risk of bias will be evaluated by
two independent reviewers, DA and RP, in line with recommendations made in the
Cochrane Handbook of Systematic Review of Interventions (Higgins 2011), Chapter 8. The
criteria will include allocation sequence, allocation concealment, blinding for participants
and outcome assessors, incomplete outcome data, and selective outcome reporting. Three
additional criteria recommended by the Cochrane EPOC group will also be included:
imbalance of outcome measures at baseline; comparability of intervention and control group
characteristics at baseline; and protection against contamination (EPOC 2009). As we expect
to find cluster study designs, we also plan to assess the risk of bias associated with selective
recruitment of participants through choice of site in these studies.
Assessment of risk of bias in each domain will be assessed as ’Low risk of bias’, ’High risk
of bias’, or ’Unclear risk of bias’, based on the guidelines from the Cochrane Handbook
(Higgins 2011), with notes indicating the reasons for each assessment included in the risk of
bias table. Conflicts in the assessments will be resolved either by consensus or by referring
to a third party (LB).
Measures of treatment effect—Where possible, a risk ratio (RR) will be provided for
the primary outcome of each trial. The RR will be defined as (number of subjects abstinent
from tobacco in the intervention group/ total number randomized to the intervention group) /
(number of subjects abstinent from tobacco in the control group/ total number randomized to
the control group). The RR is greater than 1 if the intervention is effective, and more
participants remain abstinent from tobacco in the intervention group than in the control
group. If appropriate, an estimated pooled weight average for RRs will be calculated using
the Mantel-Haenszel fixed-effect model, with 95% confidence intervals. We will conduct an
intention-to-treat analysis, including all participants enrolled at baseline whether or not they
received the intervention and counting drop-outs as continuing smokers. We will also use a
dichotomous approach for change in cigarette consumption, where changes will be
categorized as reduction by 50% or more, or no change/reduction <50%. The same methods
will be used to calculate secondary outcomes, namely abstinence from or change in use of
alcohol and other substances.
Unit of analysis issues—For cluster randomized trials, the analysis will be performed at
the level of individual but accounting for clustering. For studies that do not adjust for
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clustering, the size of the trial will be reduced to the effective sample size (Rao 1992). We
will use the original sample size from each study divided by 1.2 to account for design
effects, in keeping with other tobacco cessation trials (Gail 1992) and recommendations
drawn from the Cochrane Handbook (Higgins 2011), Chapter 16.
If studies that we have included use different statistical methods to address clustered data,
we will record whether the results presented referenced these methods and if they did,
whether this adjustment changed the significance of any observed effect.
Dealing with missing data—Missing information regarding participants will be
evaluated on an available case analysis basis as described in Chapter 16 of the Cochrane
Handbook (Higgins 2011). If information needed for the meta-analysis is missing and can
not be calculated from other data, we will attempt to contact the authors to gain access to
these data. If there has been loss of participants before baseline assessment, this review will
assume that these missing data have no effect on the final results of the analysis. Attrition
after baseline assessments will assessed and discussed between the coders (DA and RP). The
main issue to assess will be potential differential attrition between the intervention and
control groups, and differential attrition within groups that are correlated with baseline
characteristics.
Whenever possible, the number of participants lost to follow-up in each condition will be
recorded. Because loss to follow-up in the case of tobacco cessation treatment is typically
associated with continued tobacco use, participants lost to follow-up will be coded as
smokers. Analysis will be completed both including and excluding the participants lost to
follow-up and coded as continuing smokers, and differences in outcomes will be reported in
the findings. Participants lost to follow-up due to death will be excluded from the analysis
and reported separately. Participants lost to follow-up will also be counted as continuing
users of alcohol and other substances.
Assessment of heterogeneity—We will classify trials according to the subgroups listed
in Types of interventions. We will combine studies within these subgroups. For our overall
assessment, we will also pool studies that review different interventions (e.g. counselling
only versus NRT only). We will consider where there is heterogeneity due to differential
levels of baseline smoking. For example, individuals who have been abstinent before
treatment due to incarceration may be more likely to remain abstinent if offered tobacco
cessation treatment. Other factors contributing to heterogeneity may include level of tobacco
use (e.g. packs per day smoked), demographics, time to follow-up measures, and
measurement tools (e.g. self-report versus clinical assessment). If the confidence intervals of
studies have poor overlap, this usually indicates the presence of statistical heterogeneity. In
addition to visually inspecting data, we will use the I2 statistic (Higgins 2011, Chapter 9) to
identify inconsistencies between studies and groups. The Chi2 test has low power when
studies have small sample sizes, or when there are few studies. Recognizing that some level
of statistical heterogeneity is inevitable, the I2 statistic instead attempts to quantify the
potential impact of this heterogeneity on ameta-analysis. It describes the percentage of the
variability in effect estimates that is due to heterogeneity rather than sampling.
For the meta-analysis, extracted data will be pooled using a fixed-effect model. If we
identify substantial heterogeneity we will consider either using only a narrative synthesis or
the use of a random-effects model. This method would need to address the possible
influence of smaller studies, which could over- or underestimate the population treatment
effect.
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Assessment of reporting biases—There are limited statistical methods to detect
within-study selective reporting. If non-significant results are mentioned but not reported
adequately, we will assume that there was risk of bias in the meta-analysis. Unfortunately,
information sought from authors of studies may be incomplete or unreliable (Chan 2004a;
Chan 2004b). Our analysis will assess whether two key outcomes, abstinence from tobacco
and abstinence from other drugs, were present in all the included studies, and report which
studies included these outcomes and which did not. Measurements that are typically reported
jointly (e.g. abstinence from tobacco and abstinence from other drugs) should be included in
all studies, and we will assume risk of bias is high in studies where either or both do not
appear.
We will assess the risk of bias due to selective reporting of outcomes for each study rather
than for individual outcomes. Where we suspect selective outcome reporting we will contact
study authors for additional information. Should our review retrieve more than 10 included
studies, we will also create a funnel plot. Assymetrical funnel plots may be indicative of
publication bias.
Data synthesis—In addition to the meta-analysis we will report findings using narrative
synthesis. We will discuss studies individually in the event that their confidence intervals are
large and non-overlapping (small studies or small sample sizes), suggesting inconclusive
results. The results from larger and more rigorous studies will be combined. Our logic
reflects the changing nature of research in this area; we anticipate that smaller studies are
most likely to have been conducted in earlier research, when definitions of use and
abstinence, recruitment protocols, and measures were not consistent across studies. The data
will be analysed using Review Manager 5.1.
Subgroup analysis and investigation of heterogeneity—In studies that offer
extended follow-up of participants, the results may be presented for several periods of
follow-up including short-term (four weeks or less),medium-term (four weeks to six
months) and long-term (greater than six months). If data are available, we will separately
analyse studies that provide results for abstinence greater than one year. In the case of
studies with more than one follow-up assessment, we will consider whether the effect at the
longest follow-up period was larger or smaller than at earlier assessments. If data are
available, we will divide treatment modalities by intensity, creating subgroups based on the
level of pharmacotherapy or frequency of counselling.
Sensitivity analysis—Sensitivity analysis will be conducted on studies with a high risk of
bias for sequence generation and allocation concealment. The studies included in this review
will all be randomized controlled trials and given this restriction, which limits concerns
about several methodological concerns unique to cohort or case control studies, these are the
areas in which study quality is most likely to vary. As a result, we anticipate that these
factors would be most likely to bias the results of studies of treatment interventions.
Appendix 1. MEDLINE search strategy
((alcohol drinking/dt[mh:noexp] OR alcohol drinking/pc[mh:noexp] OR alcohol drinking/
px[mh:noexp] OR alcohol drinking/th[mh:noexp]) OR (alcoholism/dt[mh:noexp] OR
alcoholism/pc[mh:noexp] OR alcoholism/px[mh:noexp] OR alcoholism/rh[mh:noexp] OR
alcoholism/th[mh:noexp]) OR (heavy[tiab] AND drink*[tiab])
OR (substance withdrawal syndrome/dt[mh:noexp] OR substance withdrawal syndrome/
pc[mh:noexp] OR substance withdrawal syndrome/px[mh:noexp] OR substance withdrawal
syndrome/rh[mh:noexp] OR substance withdrawal syndrome/th[mh:noexp])
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OR (substance-related disorders/dt[mh:noexp] OR substance-related disorders/pc[mh:noexp]
OR substance-related disorders/px[mh:noexp] OR substance-related disorders/rh[mh:noexp]
OR substance-related disorders/th[mh:noexp])
OR (alcohol-related disorders/dt[mh:noexp] OR alcohol-related disorders/pc[mh:noexp] OR
alcohol-related disorders/px[mh:noexp] OR alcohol-related disorders/rh[mh:noexp] OR
alcohol-related disorders/th[mh:noexp])
OR (amphetamine-related disorders/dt[mh:noexp] OR amphetamine-related disorders/
pc[mh:noexp] OR amphetamine-related disorders/px[mh:noexp] OR amphetamine-related
disorders/rh[mh:noexp] OR amphetamine-related disorders/th[mh:noexp])
OR (cocaine-related disorders/dt[mh:noexp] OR cocaine-related disorders/pc[mh:noexp] OR
cocaine-related disorders/px[mh:noexp] OR cocaine-related disorders/rh[mh:noexp] OR
cocaine-related disorders/th[mh:noexp])
OR (inhalant abuse/dt[mh:noexp] OR inhalant abuse/pc[mh:noexp] OR inhalant abuse/
px[mh:noexp] OR inhalant abuse/rh[mh:noexp] OR inhalant abuse/th[mh:noexp])
OR (marijuana abuse/dt[mh:noexp] OR marijuana abuse/pc[mh:noexp] OR marijuana
abuse/px[mh:noexp] OR marijuana abuse/rh[mh:noexp] OR marijuana abuse/th[mh:noexp])
OR (opioid-related disorders/dt[mh] OR opioid-related disorders/pc[mh] OR opioid-related
disorders/px[mh] OR opioid-related disorders/rh[mh] OR opioid-related disorders/th[mh])
OR (phencyclidine abuse/dt[mh:noexp] OR phencyclidine abuse/pc[mh:noexp] OR
phencyclidine abuse/px[mh:noexp] OR phencyclidine abuse/rh[mh:noexp] OR
phencyclidine abuse/th[mh:noexp])
OR (substance abuse, intravenous/dt[mh:noexp] OR substance abuse, intravenous/
pc[mh:noexp] OR substance abuse, intravenous/px[mh:noexp] OR substance abuse,
intravenous/rh[mh:noexp] OR substance abuse, intravenous/th[mh:noexp]))
AND (((“smoking cessation” OR smoking cessation[mh]) OR (tobacco use
cessation[mh:noexp]) OR (tobacco use disorder[mh:noexp]) OR (tobacco,
smokeless[mh:noexp]) OR (tobacco smoke pollution[mh]) OR (tobacco[mh]) OR
(nicotine[mh]) OR ((quit*[tiab] OR stop*[tiab] OR ceas*[tiab] OR giv*[tiab]) AND
smoking[tiab]) OR (smoking/pc[mh] OR smoking/th[mh]))
AND ((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (clinical
trial[pt])) NOT (animals[mh] NOT humans[mh]))
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